Prescription drug shortages may drive up prices twice as much as they would rise with medicines in abundant supply, adding $230 million a year to U.S. drug costs, a new study estimates.
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Leadership representing the 2018 Manny Award agency and network winners and finalists share their views on various healthcare industry trends and developments.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
A recent study of DTC advertising appearing in the Journal of General Internal Medicine concluded that few broadcast ads are compliant with FDA’s guidelines. The reality, though, might not be so cut and dried.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.
A European Medicines Agency panel recommended approval of Spark Therapeutics’ gene therapy Luxturna for blindness, a move that also boosts Swiss drugmaker Novartis that bought the rights to one of the world’s costliest treatments outside the United States.
FDA Issues Statement Reaffirming Positive Benefit-Risk Profile Of Nuplazid For Patients with Hallucinations, Delusions Associated With Parkinson’s Disease Psychosis
Acadia Pharmaceuticals Inc. announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis.
Health authorities in England rejected a pricey CAR-T cell therapy from Novartis for adults with blood cancer, two weeks after endorsing Kymriah’s use in children and young people.
The U.S. Senate overwhelmingly supported a new bill aimed at opioid abuse and other addictive drugs.
Head and neck surgery patients in Hong Kong are far less likely to be prescribed opioids than patients undergoing similar surgeries in the U.S., new research shows.
Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz and Tremfya in Patients with Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company announced today the initiation of the IXORA-R head-to-head clinical trial, designed to evaluate superiority between Taltz (ixekizumab) and Tremfya (guselkumab) in adult patients with moderate-to-severe plaque psoriasis.
Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve the company’s drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).
Roche said the U.S. FDA extended by three months the review period for Tecentriq in combination therapy as a first-line treatment for a form of lung cancer.